tiprankstipranks
Xenon’s Azetukalner Marks Success in Epilepsy Treatment
Company Announcements

Xenon’s Azetukalner Marks Success in Epilepsy Treatment

Story Highlights

Xenon (XENE) has released an update.

Don't Miss our Black Friday Offers:

Xenon Pharmaceuticals Inc. presented compelling long-term data and reported quality of life improvements for adults with focal onset seizures at the 15th European Epilepsy Congress. Their drug, Azetukalner, shows more than a 90% reduction in seizure frequency in patients and has been linked to periods of seizure freedom lasting a year or longer.

For further insights into XENE stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskXenon Pharmaceuticals Unveils New Data at AES 2024
Michael MarcusJPMorgan Selects These 2 Stocks as Must-Haves for 2025
TipRanks Auto-Generated NewsdeskXenon Pharmaceuticals Reports Q3 2024 Progress and Outlook
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App